The 
A significant feature of current research in breast cancer has been the contribution of biological factors in determining prognosis in groups of patients. Amongst the factors which have been the subject of such attention recently is the protease cathepsin-D (Spyratos et al., 1989; Tandon et al., 1990) . This protease was originally identified as a protein secreted by oestrogen receptor-expressing cell lines after they were stimulated with oestrogen (Westley & Rochefort, 1979; Morisset et al., 1986) . Several forms of this protease exist, these include a precursor, procathepsin-D with a molecular weight of 52 kilodaltons (Kd). The procathepsin-D is digested proteolytically in lysosomes to a 48 Kd form and a more stable 34 Kd form (Yonezawa et al., 1988) . Biologically the molecule acts as a protease, active against basement membrane proteins and proteoglycans (Rochefort et al., 1987) . Some studies have suggested that it is mitogenic for oestrogen-depleted MCF-7 cells (Rochefort et al., 1987) ; however, other workers have not been able to confirm this finding (Stewart, 1991) . In addition, cathepsin-D secreted by MCF-7 cells participates in the mobilisation of extracellular matrix-bound basic fibroblast growth factor (Briozzo et al., 1991) .
In view of the above observations, a number of studies have been conducted on tumour homogenates from patients with breast cancer using a radioimmune assay (RIA) or Western blotting to determine whether cathepsin-D has any clinical relevance. These studies have suggested that a high cytosolic concentration of cathepsin-D is associated with a poor prognosis in primary breast cancer. Furthermore, the association of a high cytosolic concentration of cathepsin-D in patients with a poor prognosis may be independent of other prognostic factors, thus rendering, it of particular value in identifying those patients with no detectable spread of the primary tumour to the axillary lymph nodes, but who have a poor prognosis (Spyratos et al., 1989; Tandon et al., 1990 ). However, studies in which the expression of cathepsin-D has been assessed in primary breast cancer using immunohistochemical analysis find ostensibly the reverse result, namely the presence of immunocytochemically detectable cathepsin-D is associated with a better prognosis in such patients (Henry et al., 1990; Merkel et al., 1991) . These studies were not conducted on large numbers of patients and the period of follow-up was relatively short.
The disease of breast cancer has a long natural history (Brinkley & Haybittle, 1975) and it has been demonstrated that the duration of follow-up may influence the apparent significance of prognostic factors which are associated with the death of the patient (Winstanely et al., 1991a (Winstanley et al., 1991b (Winstanley et al., 1991b (Winstanley et al., 1991b) . However, after blocking the endogenous peroxidase activity, the histological sections were partially digested with 0.1% trypsin (w/v) in 0.1% CaC12 (w/v) for 0 min at 37°C (Curran & Gregory, 1977) , as described for the use of the anti-cathepsin-D serum (Henry et al., 1990) . The primary aAbbreviations: T, tumour size using the normal convention (Winstanley et al., 1991a) ; N, involved (+) or uninvolved (-) lymph nodes; G, histological grade (Winstanley et al., 1991a) .
antibody was used at 1/250 for 90 min at room temperature and a red coloration due to bound peroxidase was developed with 3-amino-9-ethyl carbazole (Polyscience Ltd, Northampton, UK). The cellular nuclei were counterstained blue with Mayers haemalum.
Slides were read independently by two observers using light microscopy. Histological sections were regarded as positive if granular cytoplasmic staining were present in malignant cells, as reported previously (Henry et al., 1990 (Rudland & Hughes, 1989) .
Consistency of immunocytochemical staining between batches was checked by including in each batch of 20 sections, a standard histological section from a known positive specimen. Sections stained without anti-cathepsin-D serum or with the primary antibody preincubated with cathepsin-D showed no positive staining. Increasing the concentration of primary antibody 5-fold failed to stain any additional sections.
Statistical analysis Follow-up data had previously been obtained from the Merseyside Cancer Registry for the patients used in this study and this data for patient survival was updated in January 1990 (Winstanley et al., 1991b) . The association of cathepsin-D with other tumour variables was assessed using a simple Chi-square test (Altman, 1991) . Since quantitation of oestrogen receptors was available for a number of the original tumours removed at the time of presentation, the association of cathepsin-D with both the presence and the level of oestrogen receptors was investigated. The presence of oestrogen receptors was set at a level above 5 fmol mg ' of cytosolic protein (Winstanley et al., 1991a) . The significance of the association between the levels of oestrogen receptor in fmol mg-' protein and cathepsin-D was evaluated by a Mann-Whitney U-test (Altman, 1991) .
The association of the production of cathepsin-D in breast cancers with patient survival was evaluated using life tables constructed from survival data according to the method described by Kaplan and Meier, and analysed using a log-rank sum (Winstanley et al., 1991b) . In order to determine whether the association of patient survival with cathepsin-D was independent of other prognostic factors shown to be significant in univariate analysis, a multivariate analysis of these factors was carried out using a Cox multiple regression model (Cox, 1972) . Other prognostic factors measured on the same group of patients included tumour size, nodal status and the presence of the oncogene c-erbB-2 (Winstanley et al., 1991b) .
Histological grade was included in this analysis, but data relating to this prognostic factor was available only for a smaller sub-set of the whole group of patients. Since the presence of oestrogen receptors has been shown previously to lack statistical significance in our group of patients, this factor was also excluded from the Cox multiple regression analysis (Winstanley et al., 1991a) . The degree of correlation between observers was assessed using the Kappa statistic, a value of greater than 0.61 was taken to represent a satisfactory level of agreement (Altman, 1991) .
Results
Of the 359 breast carcinomas evaluated, 127 (35%) of them had strong granular, cytoplasmic staining (Figure la,b) , 138 (38%) were intermediately stained in their cytoplasm ( Figure  Ic) and the remaining 94 (26%) did not stain (Figure ld) . The assessment was made only on the malignant cells; however, positive staining was also present in normal histiocytes, macrophages and blood vessel walls (Figure le) . Sometimes atypical elements of benign breast proliferations within the primary breast carcinoma were also stained for cathepsin-D, but they were always associated with staining of the carcinoma cells ( Figure If) . The mean period of follow-up of the patients was 11 years (range 8-16 years), and their average age was 57 years at the time of presentation. For the purposes of analysis both strongly stained and intermediately stained carcinomas were combined into one group of positively stained tumours.
Interobserver and intratumour variation There was some variability in the assessment of staining by the two observers on the same histological section. However, there was agreement in 90% of the slides; this corresponded to a Kappa value of 0.85, which represents a high degree of consistency between observers. In 4% of all the slides studied, intratumour heterogeneity affected these slides were regarded as negatively or positively stained. Intratumour heterogeneity was assessed by comparing the type of staining allocated when two sections from the same tumour were read independently.
Association with other tumour variables The presence of definite staining for cathepsin-D was crosstabulated with other tumour variables using a simple Chisquare test (Table II) . These included tumour size, nodal (46) 105 (41) P aAbbreviations: T, tumour size using the normal convention (Winstanley et al., 1991a) ; N, involved (+) or uninvolved (-) lymph nodes; G, histological grade (Winstanley et al., 1991a) ; Erb, the presence (+) or absence (-) of the c-erbB-2 receptor (Winstanley et al., 1991b) ; and ER, the presence (+) or absence (-) of the oestrogen receptor (Winstanley et al., 1991a Association with patient survival The association of staining for cathepsin-D and the overall survival of patients is shown in Figure 2 . The data show that the survival of patients with cathepsin-D-positive carcinomas was significantly worse than those not staining for cathepsin-D (P = 0.025). This effect became apparent early in the study during the first 2 years of patient follow-up, and persisted throughout the period of follow-up. At the end of the period of follow-up there was a 20% difference in survival between the two groups of patients. The median survival of patients whose tumours did not stain positively for cathepsin-D was 180 months compared with 147 months for those staining for this protease.
The association of cathepsin-D with survival in sub-groups of patients defined by their tumour size, nodal status, histological grade, oestrogen-receptor status and c-erbB-2 expression was analysed. In all of these sub-groups of patients staining for cathepsin-D was associated with poorer survival. However, the only group in which this observation was of statistical significance occurred in those patients not expressing the c-erbB-2 receptor (Figure 3) . The statistical validity may, however, have been influenced by the numbers of patients in the sub-groups analysed.
Multivariate analysis
In order to test whether the prognostic significance of staining for cathepsin-D was independent of other prognostic factors, the data for cathepsin-D was included in a Cox multivariate regression analysis model. In addition to cathepsin-D staining, this model included corresponding data for tumour size, nodal status, c-erbB-2 status and histological grade. Oestrogen receptor status were excluded for the reasons outlined earlier. Following analysis using this model and the only factor that emerged as an independent indicator of prognosis was nodal status (Table III) .
Discussion
Of the previously-published studies evaluating the significance of cathepsin-D as a prognostic indicator in primary breast cancer, two have reported that high levels of cathepsin-D are associated with a poorer prognosis (Tandon et al., 1990; Spyratos et al., 1989) . Both these studies used homogenised tumour specimens and RIAs or Western blotting. In contrast, two studies based on immunohistochemical assessment of cathepsin-D expression found the reverse, in that its presence was associated with better survival of the patients (Henry et al., 1990; Merkel et al., 1991) . The results from this present study, which has also used immunohistochemistry to assess production of cathepsin-D, support the findings from the earlier studies based on RIA.
It is not clear why such marked differences in the observed effect of this prognostic factor should be present between studies. However, a number of potential problems exist, and they fall into two classes, those based on detection of cathepsin-D and those based on patient groups.
In The second class of problems concerns the role played by statistics in studies assessing the association of a tumour variable with patient survival. In such studies even minor differences in the composition of the groups can have a profound effect on the apparent significance of the prognostic factor. This study is much larger than the previous study based on immunocytochemical determination of cathepsin-D by Henry et al. (1990) which contained 94 patients, although the proportion of node positive patients was similar as is true of the study by Spyratos et al. (1989) . By comparison with the study reproted by Tandon et al. (1990) , the number of patients studied was similar to that reported here. However, 75% of such patients had tumour in the axillary lymph nodes, a larger proportion than that reported in other studies. Certainly, when all studies of cathepsin-D in breast cancer are compared, there are differences in the numbers of patients, clinical staging and duration of follow-up. However, these do not seem to be consistently associated with a particular pattern of patient survival. The fact that in our study a large group of patients is required to obtain a statistically significant result may mean that small fluctuations in data can alter considerably the significance of the results. Similarly, in sub-group analysis patient numbers may be too small to observe a significant effect. The magnitude of both inter-observer error and intra-tumour heterogeneity in this study could conceivably result in such a situation.
Early interest in cathepsin-D in breast cancer arose from its property of being, in part, an oestrogen-responsive gene, at least in tissue-cultured cells (Westley & May, 1987) . For this reason expression of cathepsin-D may have seemed likely to be associated with carcinoma containing appreciable levels of oestrogen receptors. Although this has been of statistical significance in some studies (Henry et al., 1990; Tandon et al., 1990) , it is not of statistical significance in this study. The only association of statistical significance in our study was in patients with axillary lymph node metastases, a feature observed also by other workers (Tandon et al., 1990; Brouillet et al., 1990) . These observations may, in part, explain the failure of cathepsin-D to be an independent prognostic indicator in multivariate analysis. This dependent association of cathepsin-D and involved axillary lymph nodes on patient survival supports the contention that the underlying processes may themselves be dependent. One such example could be the requirement of cathepsin-D's proteolytic activity for invasion and spread to the lymph nodes draining the primary carcinoma.
In summary cathepsin-D appears to be expressed strongly in 37% and more weakly in 34% of breast carcinomas and its granular expression, probably localised to lysosomes, is associated with a poorer prognosis in these patients. However, this association with poorer prognosis may simply relate to the fact that these carcinomas are more likely to have spread to the axillary lymph nodes. In this study cathepsin-D does not have the predictive power of nodal status nor does it clearly identify sub-groups of patients with an otherwise good prognosis. Therefore, although it may be of interest in terms of tumour biology, its significance a prognostic indicator in clinical medicine is debatable.
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